CHO-K1/Human mGlu2 Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0150A | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
Metabotropic glutamate receptor 2 (mGlu2) is a class C G protein-coupled receptor widely expressed in the central nervous system, particularly at presynaptic terminals in the cerebral cortex, hippocampus, amygdala, and cerebellum. Its core function is to act as a crucial “homeostatic modulator” by coupling to Gi/o proteins, inhibiting excessive presynaptic glutamate release, thereby regulating synaptic plasticity, learning and memory processes, and mitigating excitotoxicity. Given its pivotal role in negatively modulating glutamatergic signaling, mGlu2 has emerged as a novel therapeutic target for developing treatments for psychiatric and neurological disorders such as anxiety disorders, schizophrenia, and drug addiction.
Screeningbio’s CHO-K1/Human mGlu2 cell line overexpress mGlu2 receptor and is designed to detect inhibition in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | GRM2 |
Accession Number | SNB-G-0150A |
Parental Line | CHO-K1 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
Metabotropic glutamate receptor 2 (mGlu2) is a class C G protein-coupled receptor widely expressed in the central nervous system, particularly at presynaptic terminals in the cerebral cortex, hippocampus, amygdala, and cerebellum.
Its core function is to act as a crucial “homeostatic modulator” by coupling to Gi/o proteins, inhibiting excessive presynaptic glutamate release, thereby regulating synaptic plasticity, learning and memory processes, and mitigating excitotoxicity.
Given its pivotal role in negatively modulating glutamatergic signaling, mGlu2 has emerged as a novel therapeutic target for developing treatments for psychiatric and neurological disorders such as anxiety disorders, schizophrenia, and drug addiction.